FocalTherics (NASDAQ:FOCL) Director Fran Schulz Acquires 10,000 Shares

FocalTherics (NASDAQ:FOCL) Director Fran Schulz acquired 10,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the acquisition, the director owned 15,100 shares in the company, valued at approximately $71,725. This trade represents a 196.08% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

FocalTherics Price Performance

NASDAQ FOCL opened at $4.36 on Tuesday. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. FocalTherics has a 1-year low of $1.30 and a 1-year high of $6.40. The firm has a market cap of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. The company has a 50-day moving average price of $5.38.

FocalTherics (NASDAQ:FOCL) last posted its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The business had revenue of $13.20 million for the quarter. On average, equities research analysts expect that FocalTherics will post -0.78 EPS for the current fiscal year.

Institutional Trading of FocalTherics

Several large investors have recently bought and sold shares of the company. SmartHarvest Portfolios LLC purchased a new stake in shares of FocalTherics during the first quarter valued at approximately $38,000. Lido Advisors LLC purchased a new position in shares of FocalTherics in the first quarter valued at $40,000. Kovack Advisors Inc. acquired a new stake in FocalTherics during the 4th quarter valued at $53,000. Leonteq Securities AG acquired a new stake in FocalTherics during the 4th quarter valued at $313,000. Finally, Flax Pond Capital LLC purchased a new stake in FocalTherics during the 4th quarter worth $2,623,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on FOCL. Mizuho set a $15.00 target price on shares of FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $7.75.

Key Headlines Impacting FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.